cen.acs.org

cen.acs.org
Share

cen.acs.org

 •  October 11

In a move likely to benefit Chinese citizens as well as foreign drug firms, the Chinese government has agreed to accept data from clinical trials conducted outside China for the approval of new drugs. “Applicants can directly apply for drug listing registration after the completion of the international multicenter drug clinical trials,” the China...

cen.acs.org

 •  September 15

The U.S. Food & Drug Administration wants to drive drug costs down—both the prices paid by patients and the increasingly expensive investments required during the early stages of drug development. That’s the message FDA Commissioner Scott Gottlieb delivered at the Regulatory Affairs Professionals Society conference in Washington, D.C., on Sept. 11,...

cen.acs.org

 •  June 11

Chemists track down off-target enzymes that may have contributed to a drug candidate’s neurotoxicity In January 2016, one clinical trial volunteer in France died, four others were hospitalized, and two of those went on to have long-term neurological damage. The tragedy caused widespread distress that has lingered among the public, regulators, and...

cen.acs.org

 •  June 6

Two independent research teams have determined structures of glucagon-like peptide-1 (GLP-1) receptor bound to peptide ligands, feats that could aid the discovery of new drugs for diabetes and other conditions. GLP-1 receptor is an important drug target: Binding of the peptide hormone GLP-1 activates the receptor, causing cell signaling that helps...

cen.acs.org

 •  March 20

Takeda Pharmaceutical will inject eight drug candidates into a new biotech venture, Scohia Pharma. Innovation Network Corp. of Japan, a venture capital fund partly financed by the Japanese government, will own about 70% of the venture; the rest will be held by Takeda and its subsidiary Medipal Holdings. The drug candidates are in the renal,...

cen.acs.org

 •  March 13

Throughout the U.S. presidential election season and into the Trump presidency, the high cost of drugs has made for heated discussion. A popular topic for pundits is the amount drug companies spend on marketing compared to the generally smaller sum they spend on research. Little attention, though, is paid to what it costs them to manufacture their...

cen.acs.org

 •  March 13

Beijing-based oncology drug discovery firm BeiGene is joining with the government of Guangzhou in southern China to build a $330 million biologic drug facility in the Guangzhou Development District. The venture will also fund biologic drug R&D in China. Under the agreement, $30 million will come from BeiGene and $150 million from Guangzhou. The...